Ropeginterferon alfa-2b for adults with polycythemia vera: an updated perspective from approval to real-world clinical treatment.

Krecak I, Budimir J, Sabljic Sikiric A, Lucijanic M

Open source

DOI
10.1080/17474086.2026.2755131
Published
2026 Oct 30
Container
Expert review of hematology
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/17474086.2026.2755131,
  title = {Ropeginterferon alfa-2b for adults with polycythemia vera: an updated perspective from approval to real-world clinical treatment.},
  author = {Krecak I and Budimir J and Sabljic Sikiric A and Lucijanic M},
  year = {2026},
  journal = {Expert review of hematology},
  doi = {10.1080/17474086.2026.2755131},
  url = {https://doi.org/10.1080/17474086.2026.2755131}
}

RIS

TY  - JOUR
TI  - Ropeginterferon alfa-2b for adults with polycythemia vera: an updated perspective from approval to real-world clinical treatment.
AU  - Krecak I
AU  - Budimir J
AU  - Sabljic Sikiric A
AU  - Lucijanic M
PY  - 2026
JO  - Expert review of hematology
DO  - 10.1080/17474086.2026.2755131
UR  - https://doi.org/10.1080/17474086.2026.2755131
ER  - 

APA

I, K., J, B., A, S. S., & M, L. (2026). Ropeginterferon alfa-2b for adults with polycythemia vera: an updated perspective from approval to real-world clinical treatment.. Expert review of hematology. https://doi.org/10.1080/17474086.2026.2755131

Source records